Stay updated with breaking news from Dermavant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(Albany, United States) As per DelveInsight’s assessment, globally, the Acne Vulgaris Pipeline constitutes 22+ key companies continuously working towards developing 22+ Acne Vulgaris Pipeline treatment therapies,
45.4% of subjects receiving VTAMA achieved the primary endpoint of vIGA-ADTM response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 13.9% on
ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10th consecutive... | May 16, 2023
/PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering....
A set of highlights from some of the impactful breakthroughs covered in dermatology this past month, including phase 3 trial data bimekizumab, tapinarof, and other treatments.